Press Releases April 15, 2026 08:00 PM

Stifel Financial Schedules First Quarter Financial Results Conference Call

Stifel Financial to announce Q1 2026 results and host earnings call on April 22, 2026

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
SF

Stifel Financial Corp., a diversified financial services firm, will report its first quarter 2026 financial results before market open on April 22, followed by a conference call to discuss the results. The call will feature CEO Ronald J. Kruszewski and will be accessible via phone and webcast. The release and call provide investors with insights into the company’s recent financial performance.

Stifel Financial Schedules First Quarter  Financial Results Conference Call
SF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Stifel Financial Corp. will release Q1 2026 financial results on April 22 before market open.
  • A conference call and live webcast will be held the same day at 9:30 a.m. Eastern featuring CEO Ronald J. Kruszewski.
  • Stifel provides wealth management, commercial and investment banking, trading, and research services across over 400 offices in the U.S. and global financial centers.

ST. LOUIS, April 16, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) will release its first quarter financial results before the market opens on Wednesday, April 22, 2026. The company will host a conference call to review the results at 9:30 a.m. Eastern time that same day. The conference call may include forward-looking statements.

All interested parties are invited to listen to Stifel Chairman and CEO Ronald J. Kruszewski by dialing (800) 330-6710 and referencing participant ID 2892702. A live audio webcast of the call, as well as a presentation highlighting the company’s results, will be available through Stifel’s website, www.stifel.com. For those who cannot listen to the live broadcast, a replay of the broadcast will be available through the above-referenced website beginning approximately one hour following the completion of the call.

Stifel Company Information

Stifel Financial Corp. (NYSE: SF) is a diversified financial services firm providing wealth management, commercial and investment banking, trading, and research services to individuals, institutions, and municipalities. Founded in 1890 and headquartered in St. Louis, Missouri, the firm operates more than 400 offices across the United States and in major global financial centers. As a firm where success meets success, Stifel works closely with retail and institutional clients aiming to transform opportunities into achievement. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit https://www.stifel.com/investor-relations/press-releases.

Stifel Investor Relations Contact
Joel Jeffrey, Senior Vice President
(212) 271-3610 direct
[email protected]                                


Risks

  • Conference call may include forward-looking statements that involve uncertainties related to future business conditions and company performance.
  • Economic and market fluctuations could impact Stifel’s financial results and outlook, affecting investor sentiment.
  • Potential volatility in financial markets could influence the reception of reported results given the firm's exposure to multiple financial service segments.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026